Valuation: Bolt Biotherapeutics, Inc.

Market Cap 1.21Cr 1.08Cr 99.64L 90.3L 1.69Cr 114.66Cr 1.72Cr 12Cr 4.75Cr 60Cr 4.53Cr 4.44Cr 189.39Cr P/E 2026 *
-0.24x
P/E 2027 * -0.31x
Enterprise Value 1.21Cr 1.08Cr 99.64L 90.3L 1.69Cr 114.66Cr 1.72Cr 12Cr 4.75Cr 60Cr 4.53Cr 4.44Cr 189.39Cr EV / Sales 2026 *
-
EV / Sales 2027 * 3.45x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 day+49.64%
1 week+56.75%
Current month+70.38%
1 month+74.65%
3 months+63.71%
6 months+29.81%
Current year+14.67%
1 week 3.95
Extreme 3.9467
7.78
1 month 3.38
Extreme 3.3801
7.78
Current year 3.1
Extreme 3.1
7.78
1 year 3.1
Extreme 3.1
7.78
3 years 3.1
Extreme 3.1
31.2
5 years 3.1
Extreme 3.1
280.6
10 years 3.1
Extreme 3.1
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 15/05/2024
Chief Executive Officer 55 15/05/2024
Chief Operating Officer 61 15/05/2024
Director TitleAgeSince
Director/Board Member 64 01/12/2020
Director/Board Member 55 15/05/2024
Chairman 56 04/09/2024
Date Insider Type Main position Quantity % Market Cap. Importance
18/09/26 Sell

Chief Operating Officer

-6,850 0.3556%
18/09/26 Sell

Controller/Auditor

-4,077 0.2116%
18/09/26 Sell

Chief Executive Officer

-9,132 0.4741%
Change 5-day change 1-year change 3-year change Capi.($)
+49.64%+56.75%+4.50%-67.00% 1.21Cr
+2.41%+0.29%+39.41%+72.14% 6.47TCr
-0.15%+7.50%+11.42%+71.27% 5.48TCr
+0.57%+4.60%+7.71%+90.93% 5.35TCr
+0.37%+4.67%+26.68%+49.64% 4.6TCr
-1.21%+2.32%+21.50%+118.33% 4.29TCr
-0.37%+5.07%+243.23%+789.58% 4.01TCr
+0.05%+0.21%+18.06%+48.50% 3.35TCr
+1.19%-4.98%+26.31%-0.76% 2.4TCr
-0.38%+5.68%+38.39%+28.35% 2.37TCr
Average +5.21%+7.85%+43.72%+120.10% 3.83TCr
Weighted average by Cap. +0.39%+2.73%+46.02%+142.83%

Financials

2026 *2027 *
Net sales - 35L 31.26L 28.87L 26.17L 48.95L 33Cr 49.76L 3.47Cr 1.38Cr 17Cr 1.31Cr 1.29Cr 55Cr
Net income -6.5Cr -5.8Cr -5.36Cr -4.86Cr -9.09Cr -617.04Cr -9.24Cr -65Cr -26Cr -323.29Cr -24Cr -24Cr -1.02TCr -4.75Cr -4.24Cr -3.92Cr -3.55Cr -6.64Cr -450.91Cr -6.75Cr -47Cr -19Cr -236.25Cr -18Cr -17Cr -744.83Cr
Net Debt - -
Projected Income Statement - Annual - Bolt Biotherapeutics, Inc.
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in half-life-extended multispecific antibodies designed to deliver therapies. Through the proprietary INSPIRE platform, the Company combines complementary therapeutic mechanisms in fully IgG-based molecules designed for efficacy and extended exposure. Its lead program, PRA-216, is a novel IL-4Ra/TSLP bispecific antibody in Phase II development in asthma, chronic obstructive pulmonary disease, and atopic dermatitis, with a fourth Phase II study planned in eosinophilic esophagitis. In addition to PRA-216, the Company is advancing a wholly owned pipeline of additional INSPIRE-based multispecific programs across diseases with significant unmet need. Its second program is an IL-31 containing bispecific antibody being developed initially for atopic dermatitis. The Company is open to various partnering programs, including BDC-3042: P2-ready Dectin-2 Agonist mA, Preclinical CEA ISAC and Preclinical PD-L1 ISAC.
Employees
23
Date Price Change Volume
23/26/23 $6.270 +49.64% 1,28,82,703
22/26/22 $4.190 +1.21% 14,054
21/26/21 $4.140 -3.94% 34,466
20/26/20 $4.310 +6.68% 29,274
19/26/19 $4.040 +1.00% 21,942
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Bolt Biotherapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.270USD
Average target price
41.00USD
Spread / Average Target
+553.91%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Bolt Biotherapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. BOLT Stock